Nanomedicine Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
The global nanomedicine market size reached US$ 233.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 488.3 Billion by 2028, exhibiting a growth rate (CAGR) of 13.1% during 2022-2028.
Nanomedicine refers to specialized multi-functional drugs with programmable properties used for the treatment of diseases and repairing tissues at a molecular level. It involves the use of nanoparticles, nanotubes and nanodevices, such as imaging agents, nanorobots, biochips and polymer therapeutics, for the diagnosis, treatment and prevention of a disorder and analyzing the underlying pathophysiology. The nanoparticles include metal and metal oxides, liposomes and inorganic particles, which are used for transporting the drugs and targeting difficult to reach areas in the body. As a result, nanomedicine finds extensive applications for drug delivery, diagnostic imaging, vaccines, regenerative medicines and implants.
Nanomedicine Market Trends:
The increasing prevalence of chronic medical ailments across the globe is one of the key factors creating a positive outlook for the market. Nanomedicine is highly beneficial in the treatment of oncological, neurological, urological, infectious, ophthalmological, orthopedic, immunological and cardiovascular diseases. In line with this, shifting preference for personalized medicines is also contributing to the growth of the market. Additionally, various technological advancements in the nanoscale technologies for improved diagnostic procedures are acting as other growth-inducing factors. Pharmaceutical manufacturers are using nanorobotic systems and other novel solutions for the effective administration of nanomedicines. Other factors, including improvements in the healthcare infrastructure, along with extensive research and development (R&D) activities in the field of biotechnology, are anticipated to drive the market toward growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global nanomedicine market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on nanomolecule type, product and application.
Breakup by Nanomolecule Type:
Nanoparticles
Metal and Metal Oxide Nanoparticles
Liposomes
Polymers and Polymer Drug Conjugates
Hydrogel Nanoparticles
Dendrimers
Inorganic Nanoparticles
Nanoshells
Nanotubes
Nanodevices
Breakup by Product:
Therapeutics
Regenerative Medicine
In-Vitro Diagnostics
In-Vivo Diagnostics
Vaccines
Breakup by Application:
Clinical Oncology
Infectious Diseases
Clinical Cardiology
Orthopedics
Others
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arrowhead Pharmaceuticals Inc., General Electric Company, Luminex Corporation, Merck & Co. Inc., Nanobiotix, Novartis AG, Pfizer Inc., Sanofi SA and Starpharma Holdings Limited.
Key Questions Answered in This Report
1. How big is the global nanomedicine market?
2. What is the expected growth rate of the global nanomedicine market during 2023-2028?
3. What are the key factors driving the global nanomedicine market?
4. What has been the impact of COVID-19 on the global nanomedicine market?
5. What is the breakup of the global nanomedicine market based on the nanomolecule type?
6. What is the breakup of the global nanomedicine market based on the product?
7. What is the breakup of the global nanomedicine market based on the application?
8. What are the key regions in the global nanomedicine market?
9. Who are the key players/companies in the global nanomedicine market?
- 1 Preface
- 2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
- 3 Executive Summary
- 4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
- 5 Global Nanomedicine Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
- 6 Market Breakup by Nanomolecule Type
- 6.1 Nanoparticles
- 6.1.1 Market Trends
- 6.1.2 Major Types
- 6.1.2.1 Metal and Metal Oxide Nanoparticles
- 6.1.2.2 Liposomes
- 6.1.2.3 Polymers and Polymer Drug Conjugates
- 6.1.2.4 Hydrogel Nanoparticles
- 6.1.2.5 Dendrimers
- 6.1.2.6 Inorganic Nanoparticles
- 6.1.3 Market Forecast
- 6.2 Nanoshells
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Nanotubes
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Nanodevices
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
- 7 Market Breakup by Product
- 7.1 Therapeutics
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Regenerative Medicine
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 In-Vitro Diagnostics
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 In-Vivo Diagnostics
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Vaccines
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
- 8 Market Breakup by Application
- 8.1 Clinical Oncology
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Infectious Diseases
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 8.3 Clinical Cardiology
- 8.3.1 Market Trends
- 8.3.2 Market Forecast
- 8.4 Orthopedics
- 8.4.1 Market Trends
- 8.4.2 Market Forecast
- 8.5 Others
- 8.5.1 Market Trends
- 8.5.2 Market Forecast
- 9 Market Breakup by Region
- 9.1 North America
- 9.1.1 United States
- 9.1.1.1 Market Trends
- 9.1.1.2 Market Forecast
- 9.1.2 Canada
- 9.1.2.1 Market Trends
- 9.1.2.2 Market Forecast
- 9.2 Asia-Pacific
- 9.2.1 China
- 9.2.1.1 Market Trends
- 9.2.1.2 Market Forecast
- 9.2.2 Japan
- 9.2.2.1 Market Trends
- 9.2.2.2 Market Forecast
- 9.2.3 India
- 9.2.3.1 Market Trends
- 9.2.3.2 Market Forecast
- 9.2.4 South Korea
- 9.2.4.1 Market Trends
- 9.2.4.2 Market Forecast
- 9.2.5 Australia
- 9.2.5.1 Market Trends
- 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
- 9.2.6.1 Market Trends
- 9.2.6.2 Market Forecast
- 9.2.7 Others
- 9.2.7.1 Market Trends
- 9.2.7.2 Market Forecast
- 9.3 Europe
- 9.3.1 Germany
- 9.3.1.1 Market Trends
- 9.3.1.2 Market Forecast
- 9.3.2 France
- 9.3.2.1 Market Trends
- 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
- 9.3.4.1 Market Trends
- 9.3.4.2 Market Forecast
- 9.3.5 Spain
- 9.3.5.1 Market Trends
- 9.3.5.2 Market Forecast
- 9.3.6 Russia
- 9.3.6.1 Market Trends
- 9.3.6.2 Market Forecast
- 9.3.7 Others
- 9.3.7.1 Market Trends
- 9.3.7.2 Market Forecast
- 9.4 Latin America
- 9.4.1 Brazil
- 9.4.1.1 Market Trends
- 9.4.1.2 Market Forecast
- 9.4.2 Mexico
- 9.4.2.1 Market Trends
- 9.4.2.2 Market Forecast
- 9.4.3 Others
- 9.4.3.1 Market Trends
- 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast
- 10 SWOT Analysis
- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats
- 11 Value Chain Analysis
- 12 Porters Five Forces Analysis
- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes
- 13 Price Analysis
- 14 Competitive Landscape
- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
- 14.3.1 Abbott Laboratories
- 14.3.1.1 Company Overview
- 14.3.1.2 Product Portfolio
- 14.3.1.3 Financials
- 14.3.1.4 SWOT Analysis
- 14.3.2 Arrowhead Pharmaceuticals Inc.
- 14.3.2.1 Company Overview
- 14.3.2.2 Product Portfolio
- 14.3.2.3 Financials
- 14.3.2.4 SWOT Analysis
- 14.3.3 General Electric Company
- 14.3.3.1 Company Overview
- 14.3.3.2 Product Portfolio
- 14.3.3.3 Financials
- 14.3.4 Luminex Corporation
- 14.3.4.1 Company Overview
- 14.3.4.2 Product Portfolio
- 14.3.4.3 Financials
- 14.3.4.4 SWOT Analysis
- 14.3.5 Merck & Co. Inc.
- 14.3.5.1 Company Overview
- 14.3.5.2 Product Portfolio
- 14.3.5.3 Financials
- 14.3.5.4 SWOT Analysis
- 14.3.6 Nanobiotix
- 14.3.6.1 Company Overview
- 14.3.6.2 Product Portfolio
- 14.3.6.3 Financials
- 14.3.7 Novartis AG
- 14.3.7.1 Company Overview
- 14.3.7.2 Product Portfolio
- 14.3.7.3 Financials
- 14.3.7.4 SWOT Analysis
- 14.3.8 Pfizer Inc.
- 14.3.8.1 Company Overview
- 14.3.8.2 Product Portfolio
- 14.3.8.3 Financials
- 14.3.8.4 SWOT Analysis
- 14.3.9 Sanofi SA
- 14.3.9.1 Company Overview
- 14.3.9.2 Product Portfolio
- 14.3.9.3 Financials
- 14.3.9.4 SWOT Analysis
- 14.3.10 Starpharma Holdings Limited
- 14.3.10.1 Company Overview
- 14.3.10.2 Product Portfolio
- 14.3.10.3 Financials
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook